Do you want to read an article? Please log in or register.
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Anxiety and Depression
Related content
RECOMMENDED
Anxiety and DepressionBipolar Disorder
Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study
Am J Psychiatry.
Earley W, Victoria Burgess M, Rekeda L, Dickinson R, Szatmári B, Németh G, McIntyre RS, Sachs GS, Yatham LN
doi: 10.1176/appi.ajp.
RECOMMENDED
Parkinson’s Disease
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
Lancet Neurol.
Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D, CTH-300 Study investigators.
doi: 10.1016/S1474-4422(19)30396-5.
Further Publications NeurologyFurther Publications Psychiatry
Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study
Bipolar Disord.
Earley W, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, Calabrese JR
doi: 10.1111/bdi.12852.
RECOMMENDED
Migraine and Headache
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Cephalalgia.
Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, Zhou C, Aurora SK, Yang JY, Conley RR, Oakes T
doi: 10.1177/0333102420905321.
Migraine and Headache
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Headache
Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD
doi: 10.1111/head.14138
Alzheimer’s Disease
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
Lancet Neurol
Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, Yaffe K, Saunders AM, Ratti E, TOMMORROW study investigators.
doi: 10.1016/S1474-4422(21)00043-0
Multiple Sclerosis
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment
Mult Scler
Cohen JA, Cameron MH, Goldman MD, Goodman AD, Miller AE, Rollins A, Llorens L, Patni R, Elfont R, Johnson R
doi: 10.1177/13524585211035333
RECOMMENDED
Migraine and Headache
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache
Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D'Souza DN, Pearlman EM
doi: 10.1111/head.13970
RECOMMENDED
Migraine and Headache
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Neurology.
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK
doi: 10.1212/WNL.